# Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS

> **NCT03855371** · PHASE1 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 5 (estimated)

## Conditions studied

- P53 Mutation
- Myeloid Malignancy
- MDS
- Aml

## Interventions

- **DRUG:** Decitabine
- **DRUG:** Arsenic Trioxide

## Key facts

- **NCT ID:** NCT03855371
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-10
- **Primary completion:** 2023-07
- **Final completion:** 2024-07
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2022-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03855371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03855371, "Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03855371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*